查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019482

2026-2034年胎盤幹細胞療法全球市場規模、佔有率、趨勢和成長分析報告

Global Placental Stem Cell Therapy Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 110 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計胎盤幹細胞治療市場將從 2025 年的 19.5 億美元成長到 2034 年的 104.7 億美元，2026 年至 2034 年的複合年成長率為 20.51%。

由於人們對再生醫學和先進治療方法的興趣日益濃厚，全球胎盤幹細胞療法市場正蓬勃發展。胎盤幹細胞在治療多種疾病方面展現出巨大潛力，包括自體免疫疾病、神經系統疾病和組織損傷。慢性病盛行率的不斷上升以及對有效治療方法日益成長的需求正在推動市場成長。此外，持續進行的研究和臨床試驗也在拓展幹細胞治療方法的應用範圍。

關鍵成長要素包括生物技術的進步和幹細胞研究投入的增加。與其它來源的幹細胞相比，胎盤來源幹細胞的倫理優勢正推動其在臨床應用中廣泛應用。此外，人們對個人化和再生醫學日益成長的興趣也促進了市場擴張。某些地區的政府支持和有利的法規環境也有助於這些治療方法的開發和商業化。

隨著研究的深入和更多治療方法的核准，胎盤幹細胞療法市場預計將迎來顯著成長。細胞處理和儲存技術的進步將改善治療效果並提高治療擴充性。研究機構和生技公司之間合作的加強將進一步加速創新。在新興市場，醫療基礎設施的改善和對先進治療方法認知度的提高可能會創造新的成長機會。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球胎盤幹細胞療法市場：依應用領域分類

  • 市場分析、洞察與預測
  • 骨髓惡性腫瘤和疾病
  • 先天性免疫力缺乏
  • 代謝性疾病
  • 神經系統疾病

第5章 全球胎盤幹細胞療法市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院和專科診所
  • 臨床研究機構
  • 研究機構和大學

第6章 全球胎盤幹細胞療法市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Lifebank Stem Cell Banking
    • Celularity Inc
    • Americord Registry
    • ReeLabs Pvt. Ltd
    • Pluristem Therapeutics Inc
    • Mesoblast Limited
    • ReNeuron Group Plc
    • Athersys Inc
簡介目錄
Product Code: VMR11215707

The Placental Stem Cell Therapy Market size is expected to reach USD 10.47 Billion in 2034 from USD 1.95 Billion (2025) growing at a CAGR of 20.51% during 2026-2034.

The global placental stem cell therapy market is gaining momentum due to the increasing interest in regenerative medicine and advanced therapeutic solutions. Placental stem cells have shown significant potential in treating various conditions, including autoimmune diseases, neurological disorders, and tissue damage. The growing prevalence of chronic diseases and the rising demand for effective treatment options are driving market growth. Additionally, ongoing research and clinical trials are expanding the scope of stem cell-based therapies.

Key growth drivers include advancements in biotechnology and increasing investments in stem cell research. The ethical advantages of placental stem cells compared to other sources are encouraging their adoption in clinical applications. Furthermore, the rising focus on personalized medicine and regenerative therapies is supporting market expansion. Government support and favorable regulatory frameworks in certain regions are also contributing to the development and commercialization of these therapies.

Looking ahead, the placental stem cell therapy market is expected to witness significant growth as research progresses and more therapies receive approval. Technological advancements in cell processing and storage will improve treatment outcomes and scalability. Increasing collaborations between research institutions and biotechnology companies will further accelerate innovation. Emerging markets are likely to offer new growth opportunities due to improving healthcare infrastructure and rising awareness about advanced therapies.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Application

  • Hematologic Malignancies And Disorders
  • Congenital Immunodeficiency Disorders
  • Metabolic Disorders
  • Neurological Disorders

By End User

  • Hospitals & Specialty Clinics
  • Clinical Research Organizations
  • Research Institutes & Academies

COMPANIES PROFILED

  • Lifebank Stem Cell Banking, Celularity Inc, Americord Registry, ReeLabs Pvt Ltd, Pluristem Therapeutics Inc, Mesoblast Limited, ReNeuron Group plc, Athersys Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLACENTAL STEM CELL THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Application
  • 4.2. Hematologic Malignancies And Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Congenital Immunodeficiency Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Neurological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLACENTAL STEM CELL THERAPY MARKET: BY END USER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End User
  • 5.2. Hospitals & Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Clinical Research Organizations Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Research Institutes & Academies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLACENTAL STEM CELL THERAPY MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Application
    • 6.2.2 By End User
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Application
    • 6.3.2 By End User
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Application
    • 6.4.2 By End User
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Application
    • 6.5.2 By End User
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Application
    • 6.6.2 By End User
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PLACENTAL STEM CELL THERAPY INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Lifebank Stem Cell Banking
    • 8.2.2 Celularity Inc
    • 8.2.3 Americord Registry
    • 8.2.4 ReeLabs Pvt. Ltd
    • 8.2.5 Pluristem Therapeutics Inc
    • 8.2.6 Mesoblast Limited
    • 8.2.7 ReNeuron Group Plc
    • 8.2.8 Athersys Inc